The Insulin Sparing Effect of Telmisartan in a Case of Type 2 Diabetes Mellitus Associated with Schizophrenia under Treatment of Risperidone

Yamaguchi, Kohei; Tsutsumi, Etsuro

doi:10.2169/internalmedicine.49.3107

Cited by 4 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The insulin-sparing effect of telmisartan in a case of type 2 diabetes associated with risperidone-treated SZ was also reported. Switching from candesartan to telmisartan dramatically improved glycemic control (HbA1c levels decreased from 8.3 % to 6.0 % in 6 months with reduction in insulin requirement from 62 U/day to 46 U/day in 6 months and to 18 U/day in 15 months), with significant weight reduction (from 81 kg to 65 kg in 15 months) with SZ medication not changed and without remarkable lifestyle modification [132]. Another study, conducted on group of SZ patients treated with olanzapine, showed that ARBs add-on treatment resulted in improved insulin sensitivity and attenuated insulin resistance [133].…”

Section: Psychotic Disordersmentioning

confidence: 99%

Validation of Brain Angiotensin System Blockade as a Novel Drug Target in Pharmacological Treatment of Neuropsychiatric Disorders

Wincewicz

Braszko

2017

Pharmacopsychiatry

View full text Add to dashboard Cite

Retreat in psychiatric drug development results in innovative medication decline that might be at least partially overcome by adjunct therapy. New evidence from clinical studies has shown a possible role for brain Renin-Angiotensin System (RAS) in both affective and psychotic disorders. Simultaneously, rapidly accumulating data from basic studies indicate effectiveness of central RAS blockade in much broader range of neuropsychiatric disease. Recent findings implicate brain RAS, especially Angiotensin II (Ang II), in neural pathophysiology of mental disorders through neuroendocrine modulation and effects on neurotransmitter release, mostly noradrenaline, acetylcholine and dopamine. The potential effects of angiotensin-converting-enzyme (ACE) inhibition and angiotensin type 1 receptor (AT1R) blockade on treatment of mental disorders are a matter of considerable interest. This review describes involvement of brain RAS in pathophysiology of neuropsychiatric disorders and an intriguing possibilities of improvement in pharmacological treatment outcome, where using angiotensin-converting-enzyme inhibitors (ACEI) and Angiotensin Receptor Blockers (ARB), goes beyond blood pressure control.

show abstract

Section: Psychotic Disordersmentioning

confidence: 99%

Validation of Brain Angiotensin System Blockade as a Novel Drug Target in Pharmacological Treatment of Neuropsychiatric Disorders

Wincewicz

Braszko

2017

Pharmacopsychiatry

View full text Add to dashboard Cite

show abstract

“…To the Editor I read with interest the case report "The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone", recently published by Yamaguchi and Tsutsumi (1). A striking aspect of the case was the loss of 16 kg in 15 months without remarkable life-style modification.…”

mentioning

confidence: 99%